Phase 3 Muscular Dystrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Congenital or Childhood Onset Myotonic Dystrophy Type 1 (DM1), confirmed through genetic testing, and are between 6 and 45 years old — OR you are joining directly from completing a specific earlier related study called AMO-02-MD-2-003.
- Your doctor has rated your condition as moderately severe or worse using a standard medical scale called the CGI-S (score of 3 or higher) — this applies if you are not coming directly from the earlier related study.
- You (or your parent/legal guardian) are willing and able to give written consent to participate, and if you are a child, you are also willing to agree to take part yourself.
- Your caregiver is willing and able to support your participation throughout the whole study.
- You are willing and able to follow specific food and diet rules set out by the study.
Who may not be able to join:
- Your body weight relative to your height (BMI) is below 13.5 or above 40 (confirm with trial site for exact calculation).
- You have started a new medication or changed an existing one within the last 4 weeks before joining.
- You have taken certain strong medications that affect how the body processes drugs (such as clarithromycin, ketoconazole, or ritonavir) within the last 4 weeks.
- You are currently taking certain other medications that need very precise dosing to be safe, such as warfarin or digitoxin.
- You are currently in another clinical trial testing an experimental drug, or you were in one within the last 6 months (unless it was the specific earlier related study).
- You have existing or past serious health conditions affecting your heart, brain, kidneys, liver, stomach, hormones, or breathing that could affect the study results.
- You have a known allergy to the study drug (tideglusib) or any of its ingredients, including a strawberry allergy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM, AMO Pharma
Australian sites
02 9382 5534
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Safety (Adverse Events); Safety (Adverse Events) - With Optional Expanded Access; Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.